12.08.17
Gilead Sciences has agreed to acquire Cell Design Labs Inc. in a transaction valued at $567 million, including the shares of Cell Design Labs held by Kite. Cell Design Labs is a biotechnology company developing CAR-T and T cell receptor (TCR) therapies, a new class of cancer therapies that involve genetically modifying a patient’s own immune cells to better recognize and attack cancer.
Gilead gains Cell Design’s custom cell engineering technology that it is currently developing, and its pipeline, which includes early stage treatments for prostate cancer and blood cancer.
Brian Atwood, president and chief executive officer of Cell Design Labs, Inc., said, “Bringing our robust technology platforms under the Gilead umbrella, with its outstanding research and development capabilities and commitment to innovation, provides an exciting path forward for the development of the next generation of living therapies for patients with cancer.”
“We have been working with Cell Design Labs for almost 18 months, and truly appreciate the groundbreaking nature of their technology platforms,” said David D. Chang, M.D., Ph.D., Worldwide Head of R&D and chief medical officer at Kite. “We’ve already integrated THROTTLE Switch into our CAR-T pipeline and look forward to exploring the full depth and breadth of the technologies of Gilead, Kite and Cell Design Labs to expand the cell therapy toolbox.”
Gilead gains Cell Design’s custom cell engineering technology that it is currently developing, and its pipeline, which includes early stage treatments for prostate cancer and blood cancer.
Brian Atwood, president and chief executive officer of Cell Design Labs, Inc., said, “Bringing our robust technology platforms under the Gilead umbrella, with its outstanding research and development capabilities and commitment to innovation, provides an exciting path forward for the development of the next generation of living therapies for patients with cancer.”
“We have been working with Cell Design Labs for almost 18 months, and truly appreciate the groundbreaking nature of their technology platforms,” said David D. Chang, M.D., Ph.D., Worldwide Head of R&D and chief medical officer at Kite. “We’ve already integrated THROTTLE Switch into our CAR-T pipeline and look forward to exploring the full depth and breadth of the technologies of Gilead, Kite and Cell Design Labs to expand the cell therapy toolbox.”